Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors

被引：0
|
作者：
Larry K. Golightly
Caitlin C. Drayna
Michael T. McDermott
机构：
[1] University of Colorado Hospital,Division of Endocrinology, Metabolism, and Diabetes
[2] University of Colorado Hospital Center for Drug Information,Medication Use Evaluation/Adverse Drug Reaction Coordinator
[3] Education,undefined
[4] and Evaluation,undefined
[5] University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences,undefined
[6] University of Colorado School of Medicine,undefined
[7] University of Colorado Hospital,undefined
[8] Anschutz Medical Campus Box A-003,undefined
[9] Health Sciences Library/Center for Drug Information,undefined
[10] Education,undefined
[11] and Evaluation,undefined
来源：
Clinical Pharmacokinetics | 2012年 / 51卷 / 8期
关键词：
Sitagliptin; Vildagliptin; Severe Renal Impairment; Saxagliptin; Linagliptin;
D O I：
10.1007/BF03261927
中图分类号：
学科分类号：
摘要：
Dipeptidyl peptidase-4 (DPP-4) inhibitors collectively comprise a presently unique form of disease management for persons with type 2 diabetes mellitus. The aim of this review is to compare the clinical pharmacokinetics of available DPP-4 inhibitors (alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin) for the purpose of identifying potential selection preferences according to individual patient variables and co-morbidities.
引用
收藏
页码：501 / 514
页数：13
相关论文
共 50 条
  • [21] Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
    Deacon, C. F.
    DIABETES OBESITY & METABOLISM, 2011, 13 (01): : 7 - 18
  • [22] The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
    Kanasaki, Keizo
    CLINICAL SCIENCE, 2018, 132 (04) : 489 - 507
  • [23] Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?
    Saisho, Y.
    Itoh, H.
    DIABETIC MEDICINE, 2013, 30 (04) : e149 - e150
  • [24] Dipeptidyl peptidase-4 inhibitors as new tools for cardioprotection
    Rankovic, Marina
    Jeremic, Nevena
    Srejovic, Ivan
    Radonjic, Katarina
    Stojanovic, Aleksandra
    Glisic, Milos
    Bolevich, Stefani
    Bolevich, Sergey
    Jakovljevic, Vladimir
    HEART FAILURE REVIEWS, 2021, 26 (02) : 437 - 450
  • [25] Dipeptidyl peptidase-4 inhibitors in progressive kidney disease
    Makino, Yuichi
    Fujita, Yukihiro
    Haneda, Masakazu
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2015, 24 (01): : 67 - 73
  • [26] Navigating the chemical space of dipeptidyl peptidase-4 inhibitors
    Shoombuatong, Watshara
    Prachayasittikul, Veda
    Anuwongcharoen, Nuttapat
    Songtawee, Napat
    Monnor, Teerawat
    Prachayasittikul, Supaluk
    Prachayasittikul, Virapong
    Nantasenamat, Chanin
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 4515 - 4549
  • [27] Effect of dipeptidyl peptidase-4 inhibitors on complement activation
    Hoffmann-Petersen, Ingeborg T.
    Holt, Charlotte B.
    Jensen, Lisbeth
    Hage, Camilla
    Mellbin, Linda G.
    Thiel, Steffen
    Hansen, Troels K.
    Ostergaard, Jakob A.
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2021, 37 (03)
  • [28] The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes
    O'Hara, Daniel V.
    Parkhill, Thomas R.
    Badve, Sunil V.
    Jun, Min
    Jardine, Meg J.
    Perkovic, Vlado
    DIABETES OBESITY & METABOLISM, 2021, 23 (03): : 763 - 773
  • [29] Dipeptidyl Peptidase-4 Inhibitors and Their Effects on the Cardiovascular System
    Solun, B.
    Marcoviciu, D.
    Dicker, D.
    CURRENT CARDIOLOGY REPORTS, 2013, 15 (08)
  • [30] Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome
    Kim, Kwang-il
    KOREAN CIRCULATION JOURNAL, 2018, 48 (05) : 430 - 432
12345